These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia].
    Author: Windyga J, Rzymkiewicz L, Lopaciuk S.
    Journal: Acta Haematol Pol; 1996; 27(1):27-31. PubMed ID: 8629440.
    Abstract:
    The development of antibodies to factor VIII (circulating anticoagulant, factor VIII inhibitor) is a serious complication following substitution therapy in patients with hemophilia A. These antibodies are rarely specific of human factor VIII, tending to cross-react to a variable extent with factor VIII from other species. Their neutralizing activity is usually weaker against porcine than human factor VIII. In this study, anti-human and anti-porcine factor VIII antibodies (Ab) were measured in 41 patients with severe hemophilia A. The anti-human Ab titers ranged from 0.5 to 1200 BU/ml, and the anti-porcine Ab titers ranged from 0 to 170 BU/ml. The median cross-reactivity was 28% (mean 28.9 +/- 17.2%, range 0-75%). Of the 24 patients with anti-human Ab titers > 5 BU/ml, 11 (46%) had a low anti-porcine Ab level (< or = 5 BU/ml). These patients could be treated effectively with porcine factor VIII concentrate (Hyate: C).
    [Abstract] [Full Text] [Related] [New Search]